Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Century Therapeutics, Inc. Common Stock (IPSC)
Century Therapeutics, Inc. Common Stock
XNAS:IPSC
0.53
-2.38%

Ask
$0.53 - 400.00
Bid
$0.52 - 55.00
Low
$0.51
High
$0.54
Open
$0.54
Prev Close
$0.54
52W High
1.83
52W Low
0.34
Volume
306088
Avg Vol (3m)
1019922.5
Float
45418422.47
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2836
Sector: Health Technology
Industry: Biotechnology
Date Listed: 06/18/2021
Primary Exchange: XNAS

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Phone: 215-981-4000
Address: 25 N 38th Street, 11th Floor
City: Philadelphia
State: PA
Postal Code: 19104
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
165
P/E (TTM)
-1.740000
P/B (TTM)
0.266088
EPS
-0.32
Round Lot
100
Composit FIGI
BBG00PM8N5W0
Share Class FIGI
BBG00PM8N5Y8
Share Class Shares Outstanding
86.39M
Weighted Shares Outstanding
86.39M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own IPSC. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.